Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8450325 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28975729 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL104833 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL29189684 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28408970 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11883861 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL23581849 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL742814 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11565845 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL210785 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023068822-A1 | CIGARETTE FILTER AND CIGARETTE COMPRISING SAME | 주식회사 케이티앤지 | 2023-04-27 | — | — | WO | claimed |
| US-20210169856-A1 | FORMULATIONS COMPRISING DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | claimed |
| EP-3810093-A1 | FORMULATIONS COMPRISING DOPAMINE-ß-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | Bial-Portela & CA, S.A. (PT) | 2021-04-28 | — | — | EP | claimed |
| US-20140302152-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | BIAL-PORTELA & CA., S.A. (PT) | 2014-10-09 | — | — | US | claimed |
| EP-2658528-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | Bial-Portela & CA, S.A. (PT) | 2013-11-06 | — | — | EP | claimed |
| WO-2012091593-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | BIAL - PORTELA & CA., S.A. (PT) | 2012-07-05 | — | — | WO | claimed |
| US-20090181083-A1 | Porous tablets as carriers for liquid formulations | LIFEBYCLE PHARMAS A/S (DK) | 2009-07-16 | — | — | US | claimed |
| EP-1973529-A1 | DISINTEGRATING LOADABLE TABLETS | LifeCycle Pharma A/S (DK) | 2008-10-01 | — | — | EP | claimed |
| EP-1594470-A4 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LAB INT SRL (BB) | 2007-10-17 | — | — | EP | claimed |
| WO-2007076874-A1 | DISINTEGRATING LOADABLE TABLETS | LIFECYCLE PHARMA A/S (DK) | 2007-07-12 | — | — | WO | claimed |
| EP-1765297-A2 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS | LifeCycle Pharma A/S (DK) | 2007-03-28 | — | — | EP | claimed |
| WO-2006000229-A2 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS | LIFECYCLE PHARMA A/S (DK) | 2006-01-05 | — | — | WO | claimed |
| EP-1594470-A2 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2005-11-16 | — | — | EP | claimed |
| WO-2004073632-A2 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LABORATORIES INC. (BB) | 2004-09-02 | — | — | WO | claimed |
| US-20040162333-A1 | Rapid absorption selective 5-HT agonist formulations | BIOVAIL LABORATORIES INCORPORATED (BB) | 2004-08-19 | — | — | US | claimed |
| EP-1050294-B1 | Tooth pastes | FARMACEUTICI DOTT CICCARELLI S (IT) | 2004-07-28 | — | — | EP | claimed |
| WO-2003000215-A1 | TOOTH-PASTE COMPOSITION HAVING ANTI-PLAQUE PROPERTIES | HERBARIORUM MEDICAMINUM OFFICINA ALTA BADIAE S.N.C. (IT) | 2003-01-03 | — | — | WO | claimed |
| US-6350437-B1 | TOOTH PASTES WITH IMIDOALKANEPERCARBOXYLIC ACIDS | FARMACEUTICI DOTT. CICCARELLI S.P.A. (IT) | 2002-02-26 | — | — | US | claimed |
| EP-1050294-A1 | Tooth pastes | Farmaceutici Dott. Ciccarelli S.p.A. (IT) | 2000-11-08 | — | — | EP | claimed |
| WO-2024118889-A2 | INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS | OGBURN MICHAEL (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182427-A1 | SOLID DOSAGE FORMS OF A PLASMA KALLIKREIN INHIBITOR | REZOLUTE, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-118139545-A | Cigarette filter tip and cigarette comprising same | 韩国烟草人参公社 | 2024-06-04 | — | — | CN | disclosed |
| CN-118119295-A | Filter for a cigarette and cigarette comprising a filter | 韩国烟草人参公社 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024112719-A1 | SOLID DOSAGE FORMS OF A PLASMA KALLIKREIN INHIBITOR | REZOLUTE, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-118102899-A | Method for producing a filter for cigarettes | 韩国烟草人参公社 | 2024-05-28 | — | — | CN | disclosed |
| US-11986519-B2 | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof | Schadeck, Eva Barbara (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4352075-A1 | COMPOSITIONS AND METHODS FOR TREATING PERSISTENT POSTSURGICAL PAIN | Creative Bio-Peptides Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4349776-A1 | METHOD FOR PREPARING WHITLOCKITE CRYSTALS WITHOUT GENERATION OF HYDROXYAPATITE CRYSTALS | H&Bio Co., Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4340860-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | Creative Bio-Peptides Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024050516-A2 | VARENICLINE RELATED COMPOUNDS AND METHODS FOR TREATING DISEASES AND CONDITIONS INCLUDING TOBACCO USE DISORDER | SPACERX LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240050450-A1 | Inhalable Cannabinoid Formulations | PINATA HOLDINGS INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240041782-A1 | Oral Capsule Cannabinoid Formulations | PINATA HOLDINGS INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2024020361-A2 | INHALABLE SEROTONIN RECEPTOR AGONIST FORMULATIONS | OGBURN MICHAEL (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230372345-A1 | Inhaled PDE-V Inhibitor Drugs | PINATA HOLDINGS INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023168316-A1 | ENTERIC COATED DRY POWDERED CANNABINOID FORMULATIONS | OGBURN MICHAEL (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-115180625-B | Method for concentrating silicon dioxide by phosphogypsum sedimentation | 湖北三峡实验室 | 2023-07-11 | — | — | CN | disclosed |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023068728-A1 | FILTER FOR CIGARETTES AND CIGARETTE INCLUDING THE SAME | KT & G CORPORATION (KR) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068822-A1 | CIGARETTE FILTER AND CIGARETTE COMPRISING SAME | 주식회사 케이티앤지 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068720-A1 | METHOD OF PREPARING FILTER FOR CIGARETTES | KT & G CORPORATION (KR) | 2023-04-27 | — | — | WO | disclosed |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | METANOI THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4132490-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | Metanoi Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022261321-A1 | COMPOSITIONS AND METHODS FOR TREATING PERSISTENT POSTSURGICAL PAIN | CREATIVE BIO-PEPTIDES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022256379-A1 | INHALABLE PHARMACEUTICAL FORMULATIONS | OGBURN MICHAEL (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022250492-A1 | METHOD FOR PREPARING WHITLOCKITE CRYSTALS WITHOUT GENERATION OF HYDROXYAPATITE CRYSTALS | 주식회사 오스펌 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022125882-A1 | ORAL CAPSULE CANNABINOID FORMULATIONS | OGBURN MICHAEL (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220143167-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | Pogona, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022081814-A1 | INHALABLE CANNABINOID FORMULATIONS | OGBURN MICHAEL (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11246918-B2 | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof | Schadeck, Eva Barbara (US) | 2022-02-15 | — | — | US | disclosed |
| US-11058757-B2 | Saccharide-polypeptide conjugate compositions and methods of use thereof | Pogona, LLC (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210169856-A1 | FORMULATIONS COMPRISING DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| EP-3810093-A1 | FORMULATIONS COMPRISING DOPAMINE-ß-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | Bial-Portela & CA, S.A. (PT) | 2021-04-28 | — | — | EP | disclosed |
| US-20200330579-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | LIFFEY BIOTECH LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| EP-3691677-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | Liffey Biotech Limited (IE) | 2020-08-12 | — | — | EP | disclosed |
| US-20200113993-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | Pogona, LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190343948-A1 | HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOF | Schadeck, Eva Barbara (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2019-08-29 | — | — | US | disclosed |
| WO-2019070994-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | LIFFEY BIOTECH LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| EP-3436061-A2 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | Liffey Biotech Limited (IE) | 2019-02-06 | — | — | EP | disclosed |
| WO-2018144799-A1 | HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOF | SCHADECK, Eva, Barbara (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180036330-A1 | NUCLEOTIDE PHOSPHORAMIDATE FORMULATION | MEDIVIR AB (SE) | 2018-02-08 | — | — | US | disclosed |
| EP-2285355-B1 | PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET | ATACAMA LABS OY (FI) | 2018-01-24 | — | — | EP | disclosed |
| EP-3265101-A1 | NUCLEOTIDE PHOSPHORAMIDATE FORMULATION | MEDIVIR AB (SE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2399576-B1 | Use of antibacterial compounds for the oral cavity hygiene | FARM DOTT CICCARELLI S P A (IT) | 2018-01-03 | — | — | EP | disclosed |
| CN-107405356-A | Nucleotide phosphoramidate formulations | 美迪维尔公司 | 2017-11-28 | — | — | CN | disclosed |
| WO-2017173415-A2 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | LIFFEY BIOTECH LIMITED (IE) | 2017-10-05 | — | — | WO | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
| EP-2934591-B1 | SOLID ORAL DOSAGE FORM OF TESTOSTERONE DERIVATIVE | Solural Pharma ApS (DK) | 2017-08-09 | — | — | EP | disclosed |
| EP-2285354-B1 | PROCESS FOR PREPARING A LOW DRUG LOAD TABLET | ATACAMA LABS OY (FI) | 2017-07-19 | — | — | EP | disclosed |
| US-9682148-B2 | Solid oral dosage form of testosterone derivative | Solural Pharma ApS (DK) | 2017-06-20 | — | — | US | disclosed |
| EP-2285356-B1 | PROCESS FOR PREPARING A TABLET COMPRISING METFORMIN | ATACAMA LABS OY (FI) | 2016-08-03 | — | — | EP | disclosed |
| US-20150328233-A1 | Solid Oral Dosage Form Of Testosterone Derivative | Solural Pharma ApS (DK) | 2015-11-19 | — | — | US | disclosed |
| EP-2934591-A1 | SOLID ORAL DOSAGE FORM OF TESTOSTERONE DERIVATIVE | Solural Pharma Aps (DK) | 2015-10-28 | — | — | EP | disclosed |
| US-20150164812-A1 | Porous Tablets As Carriers For Liquid Formulations | VELOXIS PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140302152-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | BIAL-PORTELA & CA., S.A. (PT) | 2014-10-09 | — | — | US | disclosed |
| US-20140179655-A1 | SOLID ORAL DOSAGE FORM OF TESTOSTERONE DERIVATIVE | Solural Pharma ApS (DK) | 2014-06-26 | — | — | US | disclosed |
| WO-2014096139-A1 | SOLID ORAL DOSAGE FORM OF TESTOSTERONE DERIVATIVE | Solural Pharma ApS (DK) | 2014-06-26 | — | — | WO | disclosed |
| EP-2683370-A1 | THIOL-CONTAINING COMPOUNDS FOR THE REMOVAL OF ELEMENTS FROM TISSUES AND FORMULATIONS THEREFOR | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2658528-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | Bial-Portela & CA, S.A. (PT) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012121798-A2 | THIOL-CONTAINING COMPOUNDS FOR THE REMOVAL OF ELEMENTS FROM TISSUES AND FORMULATIONS THEREFOR | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012091593-A1 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE | BIAL - PORTELA & CA., S.A. (PT) | 2012-07-05 | — | — | WO | disclosed |
| US-20110318283-A1 | USE OF ANTIBACTERIAL COMPOUNDS FOR THE ORAL CAVITY HYGIENE | FARMACEUTICI DOTT. CICCARELLI S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| EP-2399576-A1 | Use of antibacterial compounds for the oral cavity hygiene | Farmaceutici Dott. Ciccarelli S.p.A. (IT) | 2011-12-28 | — | — | EP | disclosed |
| EP-1973529-B1 | DISINTEGRATING LOADABLE TABLETS | LIFECYCLE PHARMA AS (DK) | 2011-05-25 | — | — | EP | disclosed |
| EP-2285354-A2 | PROCESS FOR PREPARING A LOW DRUG LOAD TABLET | Atacama Labs Oy (FI) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285355-A2 | PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET | Atacama Labs Oy (FI) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285356-A2 | PROCESS FOR PREPARING A TABLET COMPRISING METFORMIN | Atacama Labs Oy (FI) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010028843-A1 | TABLETS FOR SUBSEQUENT NANOPARTICLE SUSPENSION FILLING USING ULTRASOUND | UNIVERZA V LJUBLJANI (SI) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009135951-A2 | PROCESS FOR PREPARING A TABLET COMPRISING METFORMIN | ATACAMA LABS OY (FI) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135950-A2 | PROCESS FOR PREPARING A TABLET CONTAINING EXCIPIENTS | ATACAMA LABS OY (FI) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135949-A2 | PROCESS FOR PREPARING A VERY HIGH DRUG LOAD TABLET | ATACAMA LABS OY (FI) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135947-A2 | PROCESS FOR PREPARING A LOW DRUG LOAD TABLET | ATACAMA LABS OY (FI) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135948-A2 | PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET | ATACAMA LABS OY (FI) | 2009-11-12 | — | — | WO | disclosed |
| US-20090186081-A1 | Disintegrating Loadable Tablets | LIFECYCLE PHARMA A/S (DK) | 2009-07-23 | — | — | US | disclosed |
| US-20090181083-A1 | Porous tablets as carriers for liquid formulations | LIFEBYCLE PHARMAS A/S (DK) | 2009-07-16 | — | — | US | disclosed |
| EP-1973529-A1 | DISINTEGRATING LOADABLE TABLETS | LifeCycle Pharma A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1919300-A1 | PHOSPHORYTATED GLUCOMANNAN POLYSACCHARIDES CONTAINING 1-6 AND 1-2 LINKAGES INCREASE WEIGHT GAIN IN SWINE | Cantabria Group LCC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1916908-A1 | PHOSPHORYLATED GLUCOMANNANE POLYSACCHARIDES CONTAINING 1-6 AND 1-2 LINKAGES INCREASE WEIGHT GAIN IN POULTRY | Cantabria Group LCC (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1594470-A4 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LAB INT SRL (BB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007076874-A1 | DISINTEGRATING LOADABLE TABLETS | LIFECYCLE PHARMA A/S (DK) | 2007-07-12 | — | — | WO | disclosed |
| EP-1765297-A2 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS | LifeCycle Pharma A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| US-20070036839-A1 | Phosphorylated glucomannane polysaccharides containing 1-6 and 1-2 linkages increase weight gain in poultry | TUDURI JOSE ANTONIO MATJI | 2007-02-15 | — | — | US | disclosed |
| US-20070036840-A1 | Phosphorylated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine | CANTABRIA GROUP LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2007015932-A1 | PHOSPHORYLATED GLUCOMANNANE POLYSACCHARIDES CONTAINING 1-6 AND 1-2 LINKAGES INCREASE WEIGHT GAIN IN POULTRY | CANTABRIA GROUP LCC (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015937-A1 | PHOSPHORYTATED GLUCOMANNAN POLYSACCHARIDES CONTAINING 1-6 AND 1-2 LINKAGES INCREASE WEIGHT GAIN IN SWINE | CANTABRIA GROUP LCC (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006000229-A2 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS | LIFECYCLE PHARMA A/S (DK) | 2006-01-05 | — | — | WO | disclosed |
| EP-1594470-A2 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2005-11-16 | — | — | EP | disclosed |
| US-6830764-B2 | Applying an effective amount of alkaline earth metal salt selected from calcium and strontium salts to place where allergen exists or will exist | SHINTO FINE CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1133918-B1 | Method for denaturing allergens using calcium or strontium salts | SUMITOMO CHEMICAL CO (JP) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004073632-A2 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LABORATORIES INC. (BB) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162333-A1 | Rapid absorption selective 5-HT agonist formulations | BIOVAIL LABORATORIES INCORPORATED (BB) | 2004-08-19 | — | — | US | disclosed |
| EP-1050294-B1 | Tooth pastes | FARMACEUTICI DOTT CICCARELLI S (IT) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003000215-A1 | TOOTH-PASTE COMPOSITION HAVING ANTI-PLAQUE PROPERTIES | HERBARIORUM MEDICAMINUM OFFICINA ALTA BADIAE S.N.C. (IT) | 2003-01-03 | — | — | WO | disclosed |
| US-6350437-B1 | TOOTH PASTES WITH IMIDOALKANEPERCARBOXYLIC ACIDS | FARMACEUTICI DOTT. CICCARELLI S.P.A. (IT) | 2002-02-26 | — | — | US | disclosed |
| EP-1133918-A1 | Method for denaturing allergens using calcium or strontium salts | Sumitomo Chemical Co.,Ltd. (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1050294-A1 | Tooth pastes | Farmaceutici Dott. Ciccarelli S.p.A. (IT) | 2000-11-08 | — | — | EP | disclosed |
| US-4931273-A | Anticalculus oral composition | COLGATE-PALMOLIVE COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| US-4931273-A | Anticalculus oral composition | COLGATE-PALMOLIVE COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041782-A1 | Oral Capsule Cannabinoid Formulations | CNR2, CNR1, FAAH | SLC34A1 2304/4885LMNA 2529/4885MAPT 2058/4885 |
| US-20190343948-A1 | HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOF | SIGLEC7, FUT6, FUT5 | SLC34A1 786/4885LMNA 1632/4885MAPT 4175/4885 |
| US-20240182427-A1 | SOLID DOSAGE FORMS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK4 | SLC34A1 471/4885LMNA 2115/4885MAPT 3285/4885 |
| US-20180036330-A1 | NUCLEOTIDE PHOSPHORAMIDATE FORMULATION | SLC29A1, SAMHD1, PRPF31 | SLC34A1 42/4885LMNA 3305/4885MAPT 3019/4885 |
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | SLC34A1 445/4885LMNA 3483/4885MAPT 4121/4885 |
| US-20110318283-A1 | USE OF ANTIBACTERIAL COMPOUNDS FOR THE ORAL CAVITY HYGIENE | SOD1, ZRANB2, LPO | SLC34A1 4249/4885LMNA 3846/4885MAPT 4448/4885 |
| US-20240050450-A1 | Inhalable Cannabinoid Formulations | CNR2, CNR1, FAAH | SLC34A1 4342/4885LMNA 3039/4885MAPT 1011/4885 |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | PHOSPHO1, EGLN3, HIF1AN | SLC34A1 1791/4885LMNA 1752/4885MAPT 2393/4885 |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | PHOSPHO1, SGMS2, CHKB | SLC34A1 445/4885LMNA 3483/4885MAPT 4121/4885 |
| US-11986519-B2 | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof | SIGLEC7, FUT6, FUT5 | SLC34A1 786/4885LMNA 1632/4885MAPT 4175/4885 |
| US-20200113993-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | DNPEP, SI, IAPP | SLC34A1 1257/4885LMNA 3193/4885MAPT 3018/4885 |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | SLC34A1 445/4885LMNA 3483/4885MAPT 4121/4885 |
| US-20210169856-A1 | FORMULATIONS COMPRISING DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | DBH, MAOB, SLC6A3 | SLC34A1 1155/4885LMNA 2637/4885MAPT 601/4885 |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | SLC34A1 445/4885LMNA 3483/4885MAPT 4121/4885 |
| US-11246918-B2 | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof | SIGLEC7, FUT6, FUT5 | SLC34A1 786/4885LMNA 1632/4885MAPT 4175/4885 |
| US-11058757-B2 | Saccharide-polypeptide conjugate compositions and methods of use thereof | DNPEP, SI, IAPP | SLC34A1 1257/4885LMNA 3193/4885MAPT 3018/4885 |
| US-20200330579-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | DNPEP, SI, IAPP | SLC34A1 1257/4885LMNA 3193/4885MAPT 3018/4885 |
| US-20220143167-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | DNPEP, SI, IAPP | SLC34A1 1257/4885LMNA 3193/4885MAPT 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.